about
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical PracticeOvarian Cancer: The Fallopian Tube as the Site of Origin and Opportunities for PreventionConfronting the Care Delivery Challenges Arising from Precision MedicinePALB2: research reaching to clinical outcomes for women with breast cancerMalignant Brenner tumor associated with a germline BRCA2 mutation.Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.Counselling framework for moderate-penetrance cancer-susceptibility mutations.Cervical Cancer Genetic Susceptibility: A Systematic Review and Meta-Analyses of Recent EvidenceGenetic characterization of early onset ovarian carcinoma.Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells.When Genome Maintenance Goes Badly Awry.Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient.New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study.New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genesPathogenesis and heterogeneity of ovarian cancer.Male breast cancer in a multi-gene panel testing cohort: insights and unexpected resultsRecent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.BRCA mutation in ovarian cancer: testing, implications and treatment considerations.A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.Risk-reducing salpingectomy: Let us be opportunistic.Therapeutic targeting and patient selection for cancers with homologous recombination defects.Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.Frequency of germline PALB2 mutations among women with epithelial ovarian cancer.Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.Ovarian Cancer Prevention in High-risk Women.Somatic TP53 variants frequently confound germ-line testing results.Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.Dualistic Role of BARD1 in Cancer.Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
P2860
Q26740622-9120CF20-53B2-4B91-80C8-A919F8A1F2DEQ26747279-3104D61C-4D4B-4411-835E-F9D58169D6DBQ26747282-4856D6EF-10BB-42C0-8E62-C5D991EDCD8BQ26751309-EF7CC77C-05CA-49C0-83C3-64BA837EBEF1Q33763270-9BE1474E-7CD5-4765-965F-CDD463D771AAQ33772896-09B6AAD8-DBE5-49E9-9EEB-87299398C39DQ33911135-ACE5F4C6-64F0-4343-882C-C82B0ABF7CEBQ36077722-A1AB3343-3BF1-4F75-BF2D-49211AD58764Q36908973-8B917657-4BFE-4A93-A7B3-472ACE1C1A41Q37137451-E4460C4C-6207-4571-8F0A-937937C4F322Q37138583-F16D89D8-3BBB-4239-A9E6-CC2418C238C1Q37171584-FC85A8D6-4647-4CC9-873E-57C747EC086BQ37398841-D120A8FE-D271-4C89-A7C6-E9D29F7F2F09Q37519943-FD98B3B9-F7C1-4C12-8458-C2B2988CBFB0Q37546692-9BE85922-A6D7-45AA-B042-D2F61E113D84Q37590600-62039D6D-674F-4F95-961F-A0197908F66CQ37620476-3133FBDD-47B0-43C9-9C1F-639BF3E841AFQ37709179-722362C9-7A92-41F5-9BA4-D40216DFFC00Q38618465-3D97A47E-2B2A-411A-B878-4E5BD8A7FBD1Q38644661-BAD798C9-597C-49D3-BBBB-194113ABFB96Q38850529-29A156C3-A482-4086-8250-8A512DE4A2B9Q38905495-2015A33B-CAFC-4985-8BB3-1F529190728BQ39196159-98EC2545-E54E-4261-A740-B3A56D94EB63Q39251572-EFDB6324-676E-4EBE-A624-5C9F578C6D5BQ39309080-0A8AF4D7-A37A-4732-9572-BFC0B3AFF125Q39421659-4B55283E-5193-4B9F-B0B8-A35D517E0FD3Q40063188-E748DDD6-75B3-419B-A9BB-E3D58C79C5B0Q40580115-2597EE56-E4C8-41A4-9E96-A33EB8A36C04Q41691425-71FD042D-4B2F-4A48-B88C-48A1417EDD7FQ42379886-17332BCA-1A37-4D0B-B38E-FFF8697B1339Q42683589-93347744-2F16-4002-8228-170820991733Q43821846-C27D0949-133E-4A4A-8ABC-52C3589A2E4AQ45068704-A53B02B8-159E-4FD4-AD6D-A070E106D32BQ46051827-B463A2F9-0E60-4D06-9254-38B0F5DE3B49Q46567658-63B05E7C-4A57-4308-B404-8663C3C04D02Q46727853-4D0AC66D-ECF0-4B58-A31C-4DAE06A52278Q46782579-F444804E-DF0A-48B6-A547-7AD88B513334Q47177315-6D718145-4101-48FE-9FA6-4280E9DF7337Q47397232-2B36F794-53A8-4C91-A6FF-EBC4E286C862Q47549253-FEACB54E-7AC6-45C3-8C0A-0EBFC02C26DF
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Inherited Mutations in Women With Ovarian Carcinoma
@ast
Inherited Mutations in Women With Ovarian Carcinoma
@en
type
label
Inherited Mutations in Women With Ovarian Carcinoma
@ast
Inherited Mutations in Women With Ovarian Carcinoma
@en
prefLabel
Inherited Mutations in Women With Ovarian Carcinoma
@ast
Inherited Mutations in Women With Ovarian Carcinoma
@en
P2093
P2860
P50
P1433
P1476
Inherited Mutations in Women With Ovarian Carcinoma
@en
P2093
Elizabeth M Swisher
Heather A Lankes
John K Chan
Maria I Harrell
Mark F Brady
Michael J Birrer
Ming K Lee
Nilsa C Ramirez
Paul A DiSilvestro
P2860
P304
P356
10.1001/JAMAONCOL.2015.5495
P577
2015-12-30T00:00:00Z